Overview

Gender

male

Erik has over twenty years experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several (bio)tech companies. Previously, as a senior executive at Organon (currently Merck) he was responsible for leading the Company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600M option to acquire AM-Pharma by Pfizer, and raised more than €130M in equity and debt financing. He concluded his masters in Chemistry from the University of Utrecht and an MBA from Manchester Business School both with honors.